Morphine therapy

• US 5,593,695 A
• Filed: 05/24/1995
• Issued: 01/14/1997
• Est. Priority Date: 06/27/1994
• Status: Expired due to Term

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Hwang, Paul, Kuczynski, Anthony L., Ayer, Atul D., Merrill, Sonya
• Primary Examiner(s): Kishore, Gollamudi S.
• Application Number:
  US08/449,620
• Time in Patent Office: 601 Days
• Field of Search: 424/464, 424/465, 424/468, 424/474, 424/475, 424/479, 424/480
• US Class Current: 424/480
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
• CPC Class Codes: A61K 9/2027 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/2031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids

Abstract

A therapeutic tablet comprising morphine, poly(alkylene oxide) and poly(vinylpyrrolidone) encased by a composition comprising a cellulose polymer.

Claims

1. A therapeutic tablet comprising 50 ng to 1,200 mg of morphine;

5 mg to 750 mg of a poly(alkylene oxide) having a 100,000 to 650,000 molecular weight;

0.5 mg to 80 mg of a poly(vinyl pyrrolidone) having a 3,000 to 350,000 molecular weight; and

0 to 7.5 mg of a lubricant, which tablet is encased by a composition comprising a member selected from the group consisting of a cellulose acylate, cellulose diacylate, and cellulose triacylate.

2. The therapeutic tablet comprising morphine according to claim 1, wherein the morphine is a member selected from the group consisting of morphine hydrobromide, morphine hydrochloride, morphine mucate, morphine methylbromide, morphine oleate, morphine n-oxide, morphine sulfate, morphine acetate, morphine phosphate monobasic, morphine acetate trihydrate, morphine bi(heptafluorobutyrate), morphine bi(methylcarbamate), morphine bi(pentafluoropropionate), morphine bi(pyridine 3-carboxylate), morphine bi(trifluoroacetate), morphine bitartrate, morphine chlorohydrate, morphine sulfate pentahydrate, and morphine base.

3. The therapeutic tablet comprising morphine according to claim 1, wherein the therapeutic tablet is compressed under 1/2 to 25 ton-force of compression.

4. A method for administering 50 ng to 1,200 mg of morphine to a human, said method comprising orally administering the morphine to the human from a tablet comprising 50 ng to 1,200 mg of morphine, 5 mg to 750 mg of a poly(alkylene oxide) possessing a 100,000 to 650,000 molecular weight, and 0.5 mg to 80 mg of poly(vinyl pyrrolidone), which tablet is encased by a composition comprising a member selected from the group consisting of a cellulose acylate, cellulose diacylate, and cellulose triacylate comprising an exit passageway.